Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN).

Trial Profile

Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN).

Phase of Trial: Phase II

Latest Information Update: 31 Aug 2010

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms ALADDIN-I
  • Most Recent Events

    • 31 Aug 2010 Acronym changed to ALADDIN-I based on BE 1042741.
    • 28 Jul 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
    • 17 Jul 2006 Results reported at 10th International Conference on Alzheimer's Disease and Related Disorders (ICAD).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top